These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27810613)

  • 1. Use of atomoxetine and suicidal ideation in children and adolescents: Results of an observational cohort study within general practice in England.
    Davies M; Coughtrie A; Layton D; Shakir SA
    Eur Psychiatry; 2017 Jan; 39():11-16. PubMed ID: 27810613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
    Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
    Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study.
    Linden S; Bussing R; Kubilis P; Gerhard T; Segal R; Shuster JJ; Winterstein AG
    Pediatrics; 2016 May; 137(5):. PubMed ID: 27244795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [ADHD register: post-marketing evaluation of the benefit-risk profile of drugs and promotion of the appropriateness].
    Panei P; Arcieri R
    Recenti Prog Med; 2013 Jun; 104(6):254-61. PubMed ID: 23801229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
    Pozzi M; Carnovale C; Mazhar F; Peeters GGAM; Gentili M; Nobile M; Radice S; Clementi E
    J Clin Psychopharmacol; 2019; 39(4):386-392. PubMed ID: 31205193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
    Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Atomoxetine for treatment of children and adolescents with ADHD].
    Resen K; Pagsberg AK; Jörgens G
    Ugeskr Laeger; 2014 Mar; 176(10A):. PubMed ID: 25350704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of dystonia in children and adolescents treated with atomoxetine within the Truven MarketScan database: a retrospective cohort study.
    Meyers KJ; Upadhyaya HP; Goodloe R; Kryzhanovskaya LA; Liles-Burden MA; Kellier-Steele NA; Mancini M
    Expert Opin Drug Saf; 2018 May; 17(5):467-473. PubMed ID: 29625537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events of Atomoxetine in a Double-Blind Placebo-Controlled Study in Children with Autism.
    Tumuluru RV; Corbett-Dick P; Aman MG; Smith T; Arnold LE; Pan X; Buchan-Page KA; Brown NV; Ryan MM; Hyman SL; Hellings J; Williams C; Hollway JA; Lecavalier L; Rice RR; McAuliffe-Bellin S; Handen BL
    J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):708-714. PubMed ID: 28509573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine.
    Bangs ME; Tauscher-Wisniewski S; Polzer J; Zhang S; Acharya N; Desaiah D; Trzepacz PT; Allen AJ
    J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):209-218. PubMed ID: 18176331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine.
    Bangs ME; Wietecha LA; Wang S; Buchanan AS; Kelsey DK
    J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):426-34. PubMed ID: 25019647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine, ADHD, and the ongoing debate about increased risk of suicidal behaviors: the understudied role of kappa opioid receptor agonism Response to: Capuano A, Scavone C, Rafaniello C, et al. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation. Expert Opin Drug Saf. 2014;13 Suppl 1:S69-78.
    Fluegge K
    Expert Opin Drug Saf; 2016 Aug; 15(8):1147. PubMed ID: 27283209
    [No Abstract]   [Full Text] [Related]  

  • 19. Trends in incidence and characteristics of children, adolescents, and adults initiating immediate- or extended-release methylphenidate or atomoxetine in the Netherlands during 2001-2006.
    van den Ban E; Souverein P; Swaab H; van Engeland H; Heerdink R; Egberts T
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):55-61. PubMed ID: 20166797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Safety of Atomoxetine and Methylphenidate in Patients With Attention-Deficit/Hyperactivity Disorder in Japan: A Self-Controlled Case Series Study.
    Zheng Y; Fukasawa T; Yamaguchi F; Takeuchi M; Kawakami K
    J Atten Disord; 2024 Feb; 28(4):439-450. PubMed ID: 38084080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.